BIOMAT Database Logo BIOMAT Database Logo

Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load. 1997

H Rübsamen-Waigmann, and E Huguenel, and A Paessens, and J P Kleim, and M A Wainberg, and A Shah

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011810 Quinoxalines Quinoxaline
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D014766 Viremia The presence of viruses in the blood. Viremias

Related Publications

H Rübsamen-Waigmann, and E Huguenel, and A Paessens, and J P Kleim, and M A Wainberg, and A Shah
Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor.
January 2014, Expert review of anti-infective therapy,
H Rübsamen-Waigmann, and E Huguenel, and A Paessens, and J P Kleim, and M A Wainberg, and A Shah
[Usage of non nucleosidic inhibitors of the HIV reverse transcriptase].
April 2006, Virologie (Montrouge, France),
H Rübsamen-Waigmann, and E Huguenel, and A Paessens, and J P Kleim, and M A Wainberg, and A Shah
HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
January 2009, AIDS reviews,
H Rübsamen-Waigmann, and E Huguenel, and A Paessens, and J P Kleim, and M A Wainberg, and A Shah
TMC125 (etravirine), a second generation non-nucleoside reverse transcriptase inhibitor.
February 2007, AIDS alert,
H Rübsamen-Waigmann, and E Huguenel, and A Paessens, and J P Kleim, and M A Wainberg, and A Shah
Discovery of second generation quinazolinone non-nucleoside reverse transcriptase inhibitors of HIV-1.
January 2002, Progress in medicinal chemistry,
H Rübsamen-Waigmann, and E Huguenel, and A Paessens, and J P Kleim, and M A Wainberg, and A Shah
[Efficacy and tolerance of non nucleosidic reverse transcriptase inhibitors containing tritherapy in HIV-1 infection].
January 2005, Dakar medical,
H Rübsamen-Waigmann, and E Huguenel, and A Paessens, and J P Kleim, and M A Wainberg, and A Shah
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
February 2006, Current opinion in investigational drugs (London, England : 2000),
H Rübsamen-Waigmann, and E Huguenel, and A Paessens, and J P Kleim, and M A Wainberg, and A Shah
Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.
May 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
H Rübsamen-Waigmann, and E Huguenel, and A Paessens, and J P Kleim, and M A Wainberg, and A Shah
A novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
January 1992, Advances in experimental medicine and biology,
H Rübsamen-Waigmann, and E Huguenel, and A Paessens, and J P Kleim, and M A Wainberg, and A Shah
[RILPIVIRINE -- a novel HIV-1 non-nucleoside reverse transcriptase inhibitor].
March 2013, Klinicka mikrobiologie a infekcni lekarstvi,
Copied contents to your clipboard!